In addition to this, various treatment strategies (anti-intercellular adhesion molecule 1 (ICAM-1) antibody, anti-CD18 antibody, neutrophil inhibitory factor and IL-1 receptor antagonist) aimed at reducing the neutrophilic infiltration have shown no effect on outcome in clinical trials involving stroke patients [50]. This evidence concerns the gene ICAM1 and stroke disorder.